The prognostic role of whole-body volumetric 68GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177LU-DOTATATE
Nuclear Medicine Communications, cilt.44, sa.6, ss.509-517, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 44 Sayı: 6
- Basım Tarihi: 2023
- Doi Numarası: 10.1097/mnm.0000000000001693
- Dergi Adı: Nuclear Medicine Communications
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.509-517
- Anahtar Kelimeler: Ga-68-, DOTATATE, gastroenteropancreatic neuroendocrine tumors, Lu-177-, PET, computed tomography
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective The aim of this study is to evaluate the prognostic role of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and quantitative 68Ga-DOTATATE PET/computed tomography parameters such as maximum standardized uptake value (SUVmax), mean SUV (SUVmean), DOTATATE tumor volume (DTV), total lesion DOTATATE (TLD) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with 177Lu-DOTATATE. Material and method Our retrospective study included 21 patients with GEP-NETs treated with 177Lu-DOTATATE between January 2017 and January 2022. SUVmax, SUVmean, SUVmax/spleenSUVmax (SUVmax/Sx), DTV, TLD, SUVmean/spleenSUVmean (SUVmean/Sm), TLD/Sm values were calculated and recorded for all patients before and after 177Lu-DOTATATE treatment. Results A total of 319 metastases were detected in the patients included in the study, and a total of 68 target lesions were selected. In univariant Cox regression analysis, TLD/Sm percent change (ΔTLD/Sm) was found to be statistically significant on overall survival (OS) (P = 0.044). The 3-year survival in nonresponders was 50% (P = 0.034) based on ΔSUVmax/Sx values, 50% (P = 0.002) based on RECIST values, 50% based on ΔTDTV + new lesion values (P = 0.033), and according to ΔTTLD + new lesion values, it was 66% (P = 0.030). Conclusion In our study, we showed that SUVmax/Sx, RECIST, ΔTDTV + new lesion, and ΔTTLD + new lesion parameters can predict OS in the evaluation of response to treatment.